Biotech firm pays in whistleblower fraud settlement

“We will continue to pursue pharmaceutical companies that pay kickbacks to long-term care pharmacy providers to influence drug prescribing decisions,” said Stuart Delery, the acting assistant attorney general for the Justice Department’s Civil Division, in a statement. “Patients in skilled nursing facilities deserve care that is free of improper financial influences.”

The case was brought to the U.S. District Court in South Carolina under the whistleblower provision of the False Claims Act, a law that protects federal programs from fraud.

"Amgen denied all of these allegations that were resolved by the settlement," company spokeswoman Kelley Davenport said in a statement.